Unraveling the role of glial cell line-derived neurotrophic factor in the treatment of Parkinson's disease

Kakoty V 1 , Sarathlal KC 2 , Kaur P 1 , Wadhwa P 1 , Vishwas S 1 , Khan FR 3 Show all authors , Alhazmi AYM 4 , Almasoudi HH 5 , Gupta G 6 , Chellappan DK 7 , Paudel KR 8 , Kumar D 9 , Dua K 10 , Singh SK 11

Affiliations 

  • 1 School of Pharmaceutical Sciences, Lovely Professional University, Jalandhar-Delhi G.T Road, Phagwara, Punjab, India
  • 2 Department of Non-Communicable Disease, Translational Health Science and Technology Institute, Faridabad, India
  • 3 Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Al-Quwayiyah, Shaqra University, Riyadh, Saudi Arabia
  • 4 Pharmacy Practice Department, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia
  • 5 Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Najran University, Najran, 61441, Saudi Arabia
  • 6 Centre for Global Health Research, Saveetha Medical College, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India
  • 7 Department of Life Sciences, International Medical University, Kuala Lumpur, Malaysia
  • 8 Centre for Inflammation, Faculty of Science, School of Life Sciences, Centenary Institute and University of Technology Sydney, Sydney, NSW, 2050, Australia
  • 9 Department of Entomology and Nematology, UC Davis Comprehensive Cancer Center, University of California Davis, One Shields Avenue, Davis, CA, 95616, USA
  • 10 School of Health, University of Technology Sydney, Ultimo, NSW, 2007, Australia
  • 11 School of Pharmaceutical Sciences, Lovely Professional University, Jalandhar-Delhi G.T Road, Phagwara, Punjab, India. singhsachin23@gmail.com
Neurol Sci, 2024 Apr;45(4):1409-1418.
PMID: 38082050 DOI: 10.1007/s10072-023-07253-2

Abstract

Parkinson's disease is the second most common neurodegenerative condition with its prevalence projected to 8.9 million individuals globally in the year 2019. Parkinson's disease affects both motor and certain non-motor functions of an individual. Numerous research has focused on the neuroprotective effect of the glial cell line-derived neurotrophic factor (GDNF) in Parkinson's disease. Discovered in 1993, GDNF is a neurotrophic factor identified from the glial cells which was found to have selective effects on promoting survival and regeneration of certain populations of neurons including the dopaminergic nigrostriatal pathway. Given this property, recent studies have focused on the exogenous administration of GDNF for relieving Parkinson's disease-related symptoms both at a pre-clinical and a clinical level. This review will focus on enumerating the molecular connection between Parkinson's disease and GDNF and shed light on all the available drug delivery approaches to facilitate the selective delivery of GDNF into the brain paving the way as a potential therapeutic candidate for Parkinson's disease in the future.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications